|
COPYRIGHT 2002 International Medical News Group
SAN FRANCISCO -- An exciting major expansion in systemic therapeutic options for serious opportunistic fungal infections is getting underway, Dr. Thomas J. Walsh said at the annual meeting of the Infectious Diseases Society of America.
Within coming months, look for voriconazole (Vfend, Pfizer), the first of the second-generation triazoles, to reach the marketplace. Posaconazole (Schering-Plough) and ravuconazole (Eisai/ Bristol-Myers Squibb) are others in this class in clinical trials. Also, the role of another novel class...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
